27.11.2012 Views

Lake Como 2|4 October 2011 - CHIMICA Oggi/Chemistry Today

Lake Como 2|4 October 2011 - CHIMICA Oggi/Chemistry Today

Lake Como 2|4 October 2011 - CHIMICA Oggi/Chemistry Today

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER<br />

ABSTRACT<br />

BIOGRAPHY<br />

Continuous manufacturing<br />

FDA perspective on submissions and implementation<br />

Christine Moore<br />

FDA - USA<br />

Christine Moore<br />

Christine Moore is the Deputy Director for Science and Policy of FDA’s Offi ce of New Drug<br />

Quality Assessment.<br />

She started at the agency in 2004 as the Branch Chief of the newly created Manufacturing<br />

Science group.<br />

Christine has been actively involved in FDA’s Quality by Design initiatives and was a member<br />

of the expert working group for ICH Q8(R).<br />

Prior to joining the FDA, she worked for 10 years in API process development and<br />

scale-up at Pfi zer and Searle/Pharmacia.<br />

Her background is in chemical and biochemical engineering, with<br />

degrees from Northwestern University and Massachusetts Institute of<br />

Technology.<br />

Continuous manufacturing is a technology actively being explored for pharmaceutical manufacturing, both by academia and<br />

industry. With its lower equipment size and higher throughput, continuous manufacturing has the potential to provide economic<br />

and safety benefi ts. From a quality perspective, the online monitoring and control used in continuous manufacturing can lead<br />

to increased product quality assurance and implementation of real-time real testing (RTRT) approaches. This presentation<br />

will discuss the regulatory implications of continuous manufacturing from a US FDA viewpoint. Both scientifi c and regulatory<br />

considerations will be provided for developing and implementing a continuous manufacturing process.<br />

18<br />

<strong>Lake</strong> <strong>Como</strong><br />

<strong>2|4</strong> <strong>October</strong> <strong>2011</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!